TAZ target gene ITGAV regulates invasion and feeds back positively on YAP and TAZ in liver cancer cells.


Journal

Cancer letters
ISSN: 1872-7980
Titre abrégé: Cancer Lett
Pays: Ireland
ID NLM: 7600053

Informations de publication

Date de publication:
31 03 2020
Historique:
received: 27 09 2019
revised: 13 12 2019
accepted: 25 12 2019
pubmed: 7 1 2020
medline: 6 10 2020
entrez: 7 1 2020
Statut: ppublish

Résumé

The Hippo pathway effectors yes-associated protein (YAP) and WW domain containing transcription regulator 1 (TAZ/WWTR1) support tumor initiation and progression in various cancer entities including hepatocellular carcinoma (HCC). However, to which extent YAP and TAZ contribute to liver tumorigenesis via common and exclusive molecular mechanisms is poorly understood. RNAinterference (RNAi) experiments illustrate that YAP and TAZ individually support HCC cell viability and migration, while for invasion additive effects were observed. Comprehensive expression profiling revealed partly overlapping YAP/TAZ target genes as well as exclusively regulated genes. Integrin-αV (ITGAV) is a novel TAZ-specific target gene, whose overexpression in human HCC patients correlates with poor clinical outcome, TAZ expression in HCCs, and the abundance of YAP/TAZ target genes. Functionally, ITGAV contributes to actin stress fiber assembly, tumor cell migration and invasion. Perturbation of ITGAV diminishes actin fiber formation and nuclear YAP/TAZ protein levels. We describe a novel Hippo downstream mechanism in HCC cells, which is regulated by TAZ and ITGAV and that feedbacks on YAP/TAZ activity. This mechanism may represent a therapeutic target structure since it contributes to signal amplification of oncogenic YAP/TAZ in hepatocarcinogenesis.

Identifiants

pubmed: 31904487
pii: S0304-3835(19)30666-4
doi: 10.1016/j.canlet.2019.12.044
pii:
doi:

Substances chimiques

Adaptor Proteins, Signal Transducing 0
Integrin alphaV 0
Trans-Activators 0
Transcription Factors 0
Transcriptional Coactivator with PDZ-Binding Motif Proteins 0
WWTR1 protein, human 0
YAP-Signaling Proteins 0
YAP1 protein, human 0
Protein Serine-Threonine Kinases EC 2.7.11.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

164-175

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no competing financial interests to disclose.

Auteurs

Sofia M E Weiler (SME)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Teresa Lutz (T)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Michaela Bissinger (M)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Carsten Sticht (C)

Medical Faculty Mannheim, Medical Research Center, University of Heidelberg, Mannheim, Germany.

Maria Knaub (M)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Norbert Gretz (N)

Medical Faculty Mannheim, Medical Research Center, University of Heidelberg, Mannheim, Germany.

Peter Schirmacher (P)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany.

Kai Breuhahn (K)

Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany. Electronic address: kai.breuhahn@med.uni-heidelberg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH